文献速递基础与转化研究临床试验与 GCP

序贯CD7 CAR T细胞治疗与异基因造血干细胞移植(不进行GVHD预防)

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
PubMed 文献 · N Engl J Med · 2024-01-01

这项研究在10例复发或难治性CD7阳性白血病或淋巴瘤患者中测试了序贯CD7 CAR T细胞治疗与单倍体造血干细胞移植(不进行药物清髓或GVHD预防)的「一体化」策略;CAR T治疗后全部10例达到完全缓解伴不完全血液学恢复,中位随访15.1个月后6例维持微小残留病阴性完全缓解,估计1年总生存率68%(95%CI 43至100),1年无病生存率54%(95%CI 29至100)。

要点

  • CAR T治疗后10例均达完全缓解伴不完全血液学恢复及4级全血细胞减少。
  • 单倍体移植后8例完全供者嵌合,3例发生2级移植相关急性GVHD。
  • 估计1年总生存率68%(95%CI 43至100),1年无病生存率54%(95%CI 29至100)。

核心结论

  • 研究结果提示序贯CD7 CAR T细胞治疗与单倍体造血干细胞移植安全有效,缓解和严重但可逆的不良事件。
  • 该策略为不适合常规异基因造血干细胞移植的CD7阳性肿瘤患者提供了一种可行方法。

研究设计与样本

  • 前瞻性研究,纳入10例复发或难治性CD7阳性白血病或淋巴瘤患者,采用序贯CD7 CAR T细胞治疗与单倍体造血干细胞移植的「一体化」策略。
  • CAR T细胞治疗达完全缓解伴不完全血液学恢复后,患者接受单倍体造血干细胞移植,不进行药物清髓或GVHD预防药物。
  • 密切监测毒性反应和疗效。

主要发现

  • CAR T细胞治疗后,全部10例患者达完全缓解伴不完全血液学恢复及4级全血细胞减少。
  • 单倍体造血干细胞移植后,1例于第13天死于感染性休克和脑炎,8例达完全供者嵌合,1例为自体造血。
  • 3例发生2级移植相关急性GVHD。
  • CAR T细胞治疗后中位随访15.1个月(范围3.1至24.0),6例维持微小残留病阴性完全缓解,2例CD7阴性白血病复发,1例于3.7个月死于感染性休克。
  • 估计1年总生存率为68%(95%CI 43至100),估计1年无病生存率为54%(95%CI 29至100)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSCT) has the potential for long-term tumor elimination. However, pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control is unclear. METHODS: We tested a novel "all-in-one" strategy consisting of sequential CD7 CAR T-cell therapy and haploidentical HSCT in 10 patients with relapsed or refractory CD7-positive leukemia or lymphoma. After CAR T-cell therapy led to complete remission with incomplete hematologic recovery, patients received haploidentical HSCT without pharmacologic myeloablation or GVHD prophylaxis drugs. Toxic effects and efficacy were closely monitored. RESULTS: After CAR T-cell therapy, all 10 patients had complete remission with incomplete hematologic recovery and grade 4 pancytopenia. After haploidentical HSCT, 1 patient died on day 13 of septic shock and encephalitis, 8 patients had full donor chimerism, and 1 patient had autologous hematopoiesis. Three patients had grade 2 HSCT-associated acute GVHD. The median follow-up was 15.1 months (range, 3.1 to 24.0) after CAR T-cell therapy. Six patients remained in minimal residual disease-negative complete remission, 2 had a relapse of CD7-negative leukemia, and 1 died of septic shock at 3.7 months. The estimated 1-year overall survival was 68% (95% confidence interval [CI], 43 to 100), and the estimated 1-year disease-free survival was 54% (95% CI, 29 to 100). CONCLUSIONS: Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers a feasible approach for patients with CD7-positive tumors who are ineligible for conventional allogeneic HSCT. (Funded by the National Natural Science Foundation of China and the Key Project of Science and Technology Department of Zhejiang Province; ClinicalTrials.gov numbers, NCT04599556 and NCT04538599.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Hu Y, Zhang M, Yang T, et al. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. N Engl J Med. 2024. PMID: 38657244. doi:10.1056/NEJMoa2313812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。